2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine 2018, 24: 749-757. PMID: 29867230, PMCID: PMC6721896, DOI: 10.1038/s41591-018-0053-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, Renal CellFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateKidney NeoplasmsMaleMiddle AgedMutationSunitinibTreatment OutcomeConceptsProgression-free survivalPFS hazard ratioRenal cell carcinomaHazard ratioPD-L1Cell carcinomaTreatment-naive metastatic renal-cell carcinomaRandomized phase 2 studyMetastatic renal cell carcinomaInflammatory gene expression signatureExploratory biomarker analysisPhase 2 studyImmune checkpoint blockadeCo-primary endpointsPrediction of outcomeAtezolizumab monotherapyCheckpoint blockadeGene expression signaturesNeoantigen burdenT effectorsClinical activityAtezolizumabBevacizumabTumor mutationsSunitinib
2015
Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM. Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo. The Journal Of Immunology 2015, 194: 950-959. PMID: 25539810, PMCID: PMC4380504, DOI: 10.4049/jimmunol.1401686.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntigens, SurfaceAntineoplastic Combined Chemotherapy ProtocolsCTLA-4 AntigenCytokinesGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunophenotypingIpilimumabLymphocytes, Tumor-InfiltratingNeoplasmsNivolumabProgrammed Cell Death 1 ReceptorSignal TransductionT-Lymphocyte SubsetsConceptsPD-1T cellsCTLA-4Checkpoint blockadeCombination therapyReceptor occupancyCombination immune checkpoint blockadeCTLA-4 immune checkpointsPD-1 receptor occupancyTransitional memory T cellsAnti-PD-1 therapyAnti CTLA-4Immune-based combinationsPD-1 blockadeSoluble IL-2RImmune checkpoint blockadeNK cell functionMemory T cellsTherapy-induced changesT cell activationTumor T cellsHuman T cellsRemarkable antitumor effectImmunologic changesImmunologic effects
2009
Genome-wide screen of promoter methylation identifies novel markers in melanoma
Koga Y, Pelizzola M, Cheng E, Krauthammer M, Sznol M, Ariyan S, Narayan D, Molinaro AM, Halaban R, Weissman SM. Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Research 2009, 19: 1462-1470. PMID: 19491193, PMCID: PMC2720187, DOI: 10.1101/gr.091447.109.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdultAgedBiomarkers, TumorCells, CulturedCluster AnalysisCollagenCollagen Type IDNA MethylationFemaleGene Expression ProfilingGenome-Wide Association StudyGenome, HumanHSP20 Heat-Shock ProteinsHumansInfant, NewbornMaleMelanomaMetallothioneinMiddle AgedMolecular ChaperonesNuclear ProteinsNucleoplasminsOligonucleotide Array Sequence AnalysisPhosphoproteinsPromoter Regions, GeneticProteinsReproducibility of ResultsReverse Transcriptase Polymerase Chain ReactionSequence Analysis, DNATumor Cells, CulturedConceptsDifferential gene expressionGene expressionPromoter methylationGenome-wide promoter methylationGenome-wide integrative analysisPromoter CpG contentMethylation markersGenome-wide screenSequencing of bisulfiteTranscription start siteMelanoma cell strainsCell strainsTranscriptional machineryNovel genesEpigenetic modificationsDNA methylationIdentifies novel markersStart siteSnap-frozen tissuesCpG contentAdult melanocytesIntegrative analysisReal-time reverse transcriptase PCRHuman diseasesMethylationIntegrative Analysis of Epigenetic Modulation in Melanoma Cell Response to Decitabine: Clinical Implications
Halaban R, Krauthammer M, Pelizzola M, Cheng E, Kovacs D, Sznol M, Ariyan S, Narayan D, Bacchiocchi A, Molinaro A, Kluger Y, Deng M, Tran N, Zhang W, Picardo M, Enghild JJ. Integrative Analysis of Epigenetic Modulation in Melanoma Cell Response to Decitabine: Clinical Implications. PLOS ONE 2009, 4: e4563. PMID: 19234609, PMCID: PMC2642998, DOI: 10.1371/journal.pone.0004563.Peer-Reviewed Original ResearchConceptsDNA damage responseMelanoma cell responseDamage responseGene expressionIntegrative analysisDifferential gene expressionMelanoma cell strainsGene expression profilesDNA promoter methylationP53-independent mannerHistone modificationsImproved combination therapiesEpigenetic modifiersTGFbeta pathwayBioinformatics analysisProtein stabilityEpigenetic modulationResistant melanoma cellsExpression profilesGrowth arrestPromoter methylationCancer cellsCell strainsProteasome inhibitorsPTEN mutations
2005
Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer
McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM. Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer. Clinical Cancer Research 2005, 11: 5188-5194. PMID: 16033835, DOI: 10.1158/1078-0432.ccr-05-0158.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsCase-Control StudiesFemaleFollow-Up StudiesGene Expression ProfilingHumansMiddle AgedMultivariate AnalysisOligonucleotide Array Sequence AnalysisPrognosisReceptors, TNF-Related Apoptosis-Inducing LigandReceptors, Tumor Necrosis FactorSurvival AnalysisConceptsEarly-stage breast cancerTRAIL-R2 expressionBreast cancerPrognostic valueTRAIL-R2TRAIL-R1Normal breast specimensTumor necrosis factor-related apoptosis-inducing ligand receptor 1Lymph node involvementSubset of patientsBreast cancer patientsIndependent prognostic markerTRAIL-R1 expressionNormal breast epitheliumTRAIL receptor expressionLigand receptor 1Apoptosis-inducing ligand receptor 1Adjuvant treatmentNode involvementNodal statusPathologic variablesTumor sizeCancer patientsClinical trialsPrognostic marker